DEBx Medical
- Company typePrivate
- Founded2019
- HeadquartersRotterdam, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
DEBx Medical firmographics
Firmographics- Name
- DEBx Medical
- Website
- https://debx-medical.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
DEBx Medical industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Skilled Nursing Care Facilities (8051)
- akta.pro primary industry
- Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)
- akta.pro secondary industry
- Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where DEBx Medical is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
DEBx Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- DEBRICHEM Product Sales: DEBx Medical generates revenue through the commercialization of its wound care product DEBRICHEM, targeting healthcare providers treating chronic infected wounds.
Go-to-market motion1 record
DEBx Medical product offering
Product offeringCore offering
DEBx Medical develops and commercializes DEBRICHEM, an innovative wound care product specifically designed for treating chronic infected wounds. The product is intended for healthcare providers, including hospitals, wound care centers, and clinical practitioners managing patients with persistent wound infections where conventional treatments often fail.
Product overview
DEBx Medical is a Dutch medtech company offering a single unified product, DEBRICHEM (also stylized as DEBRICHEM®), which is an innovative wound care solution designed for treating chronic infected wounds. The company is using a €10 million funding round from TVM Capital Healthcare to commercialize DEBRICHEM and establish regional presence in the MENA region.
Differentiator
Problem solved
Functional benefit
Brands
- DEBRICHEM: Wound care product designed for treating chronic infected wounds.
- DEBRICHEM®
Products and services
- DEBRICHEM
Companies that use DEBx Medical
Customer profileSegments1 record
Ideal customer profiles1 record
DEBx Medical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
DEBx Medical partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights4 records
DEBx Medical competitors and assessment
Company assessmentDirect peers
- MiMedx: Commercial-stage regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for chronic wound healing — a directly comparable novel-therapy peer in the same end market.
- Organogenesis: Specialist in regenerative wound care biologics (e.g., Apligraf, Dermagraft) targeting chronic wounds such as diabetic foot ulcers, a directly comparable commercial-stage peer in novel wound therapies.
- Integra LifeSciences: Sells regenerative wound care matrices (Integra Dermal Regeneration Template) and tissue-based products for chronic and complex wounds; closely comparable in clinical positioning and end customers.
Broad incumbents
- 3M Health Care (Solventum): Broad medical device business with a wound care portfolio (including former Acelity/KCI assets) such as V.A.C. therapy and advanced dressings; competes head-to-head with DEBx Medical in chronic wound care.
- Smith & Nephew: Global medical devices leader with a sizable advanced wound care franchise (e.g., PICO, ACTICOAT), directly competing with DEBRICHEM in chronic wound management across hospitals and home care.
- ConvaTec: Specialist in advanced wound dressings and skin care (AQUACEL, Granulox), serving the same chronic wound care providers that DEBx Medical targets with DEBRICHEM.
- Mölnlycke Health Care: Major wound care and surgical solutions company (Mepilex, Mepitel), overlapping with DEBx Medical's customer base of hospitals and wound care clinics treating chronic infected wounds.
- Coloplast: Established player in wound and skin care with a portfolio of dressings and antimicrobial products, competing for the same chronic wound care budgets as DEBRICHEM.
Emerging players
- PolyNovo: Emerging medtech with a novel dermal matrix (NovoSorb) for complex and chronic wounds; a smaller, focused peer in advanced/regenerative wound care comparable in company stage.
Others
- Cardinal Health (Medical / Wound Care): Major medical products distributor that supplies wound care dressings and devices to hospitals, providing the channel through which DEBx Medical's product could reach end users.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
DEBx Medical social profiles
Digital presenceDEBx Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
DEBx Medical leadership team
Management profileNumber of profiles
DEBx Medical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DEBx Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DEBx Medical
What does DEBx Medical do?
DEBx Medical develops and commercializes DEBRICHEM, an innovative wound care product specifically designed for treating chronic infected wounds. The product is intended for healthcare providers, including hospitals, wound care centers, and clinical practitioners managing patients with persistent wound infections where conventional treatments often fail.
Is DEBx Medical a public or private company?
DEBx Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was DEBx Medical founded?
DEBx Medical was founded in 2019. It employs 11 to 50 people.
Where is DEBx Medical based?
DEBx Medical is headquartered in Rotterdam, Netherlands, in the Europe region.
How does DEBx Medical make money?
One revenue line is on record: DEBRICHEM Product Sales.
Who are DEBx Medical's main competitors?
Direct peers on record are MiMedx, Organogenesis and Integra LifeSciences. Broad incumbents are 3M Health Care (Solventum), Smith & Nephew, ConvaTec, Mölnlycke Health Care and Coloplast. PolyNovo is listed as an emerging player. Cardinal Health (Medical / Wound Care) is listed as an others.
Does DEBx Medical have an API?
No public API is recorded for DEBx Medical.
What industry is DEBx Medical in?
DEBx Medical's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation), with a secondary code of HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 339113 and its SIC code is 3841.